Patient follow-up after treatment of breast, colorectal and prostate cancer

Czech version

Authors: Tomáš Büchler
Authors‘ workplace: Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
Published in: Vnitř Lék 2014; 60(Suppl 2): 15-20
Category: 70th Birthday - prof. MUDr. Jiří Vorlíček, CSc.

Overview

The prevalence of malignant tumors (not including non-melanoma skin cancer) in the Czech Republic exceeds 350,000 persons, including patients with active disease and those with a history of malignancy. A substantial portion of this population are in long-term complete remission after cancer treatment. These patients are at high risk of cancer recurrence and long-term complications associated with previous cancer therapy. The aim of this review is to summarize current follow-up recommendations for the three most common solid tumor types, including breast, colorectal, and prostate cancer.

Key words:
breast cancer – colorectal cancer – follow-up – prevalence – prostate cancer

Sources

1. Ústav zdravotnických informací a statistiky. Dostupné z WWW: <http://www.uzis.cz/category/tematicke-rady/zdravotnicka-statistika/novotvary>.

2. Foretová L. Jak sledovat pacienty s výskytem nádoru v rodině? Interní Med 2010; 12(10): 510–515.

3. Dispenzarizace dědičných nádorových syndromů. Česká lékařská společnost. Dostupné z WWW: <http://www.cls.cz/dokumenty/dispenzarizace_dedicnych_nador_syndromu.pdf>.

4. Senkus E, Kyriakides S, Penault-Llorca F et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi7-vi23. Dostupné z DOI: <http://doi: 10.1093/annonc/mdt284>.

5. Khatcheressian JL, Hurley P, Bantug E et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31879: 961–965.

6. Meyerhardt JA, Mangu PB, Flynn PJ et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 2013; 31(35): 4465–4470.

7. Labianca R, Nordlinger B, Beretta GD et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi64-vi72. Dostupné z DOI: <http://doi: 10.1093/annonc/mdt354>.

8. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2002; (1): CD002200.

9. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348(10): 883–890.

10. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012; 9(5): 259–267.

11. Park SB, Goldstein D, Krishnan AV et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013; 63(6): 419–437.

12. Skolarus TA, Wolf AM, Erb NL et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014; 64(4): 225–249.

13. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012; 223(1): 1–68.

14. Kushi LH, Doyle C, McCullough M et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012; 62(1): 30–67.

15. NCCN Clinical Practice Guidelines in Oncology. Survivorship V1.2014.Dostupné z WWW: <http://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf>.

16. Nešpor K. Jaké je „zdravé“ množství alkoholu? Interní Med 2008; 10(4): 200.

17. Buchler T, Kubankova P, Boublikova L et al. Detection of second malignancies during long-term follow-up of testicular cancer survivors. Cancer 2011; 117(18): 4212–4218.

18. VanderWalde AM, Hurria A. Second malignancies among elderly survivors of cancer. Oncologist 2011; 16(11): 1572–1581.

19. Vyhláška Ministerstva zdravotnictví ČR ze dne 17. prosince 2009 o stanovení obsahu a časového rozmezí preventivních prohlídek. Sbírka zákonů č 3/2010. Dostupné na www: <http://www.sagit.cz/pages/sbirkatxt.asp?zdroj=sb10003&cd=76&typ=r>.

20. Calandrino R, Ardu V, Corletto D et al. Evaluation of second cancer induction risk by CT follow-up in oncological long-surviving patients. Health Phys 2013; 104(1): 1–8.

21. Watson EK, Rose PW, Neal RD et al. Personalised cancer follow-up: risk stratification, needs assessment or both? Br J Cancer 2012; 106(1): 1–5.

22. Vorlíček J, Abrahámová J, Büchler T. Kapitola II: Novotvary. Promítnutí pokroků lékařské vědy do funkčního hodnocení zdravotního stavu a pracovní schopnosti ve vztahu k zdravotním postižením podle Mezinárodní klasifikace nemocí a s přihlédnutím k Mezinárodní klasifikaci funkčních schopností. Závěrečná zpráva projektu výzkumu MPSV ČR HR 163/07. MP SV ČR, Praha 2008. Dostupné z WWW: <http://www.mpsv.cz/files/clanky/6131/MPSV_A3.pdf>.

23. Česká správa sociálního zabezpečení. Statistické ročenky. Dostupné z WWW: <http://www.cssz.cz/cz/o-cssz/informace/informacni-materialy/statisticke-rocenky.htm>.

24. van Harten WH, van Noort O, Warmerdam R et al. Assessment of rehabilitation needs in cancer patients. Int J Rehabil Res 1998; 21(3): 247–257.

25. Black JF, Kishner S, Yadav RR et al. Cancer and rehabilitation, 2013. Dostupné z WWW: <http://emedicine.medscape.com/article/320261-overview>.

26. Grant M, Economou D, Ferrell BR. Oncology nurse participation in survivorship care. Clin J Oncol Nurs 2010; 14(6): 709–715.

27. Hudson SV, Miller SM, Hemler J et al. Adult cancer survivors discuss follow-up in primary care: 'not what i want, but maybe what i need'. Ann Fam Med 2012; 10(5): 418–427.

28. From Cancer Patient to Cancer Survivor: Lost in Transition. Institue of Medicine of the National Academies (IOM). Dostupné z WWW: <http://www.iom.edu/Reports/2005/From-Cancer-Patient-to-Cancer-Survivor-Lost-in-Transition.aspx>.

29. Salz T, Oeffinger KC, McCabe MS et al. Survivorship care plans in research and practice. CA Cancer J Clin 2012; 62(2): 101–117. Dostupné z DOI: <http://onlinelibrary.wiley.com/doi/10.3322/caac.20142/pdf>.